About
Albus Health’s contactless multi-sensor platform monitors critical night-time (nocturnal) symptoms without any patient burden. The range of symptom metrics the platform monitors makes it ideal for use in chronic Respiratory, Cardiovascular and Neurological diseases, among others.
Having acquired regulatory approval for the US and Europe, the product is commercialised in the ~£4 billion Pharma clinical trials market (including de-centralised clinical trials), with inbound paid pilots from multiple clients, including AstraZeneca, and others in the pipeline. The platform is currently being extended to preventative healthcare through remote monitoring in high burden patients at two of the UK’s largest paediatric hospitals in a project fully funded by the UK’s Department of Health. Our team includes clinicians who lead medicine departments at University of Oxford and King’s College London, technology experts who have commercialised deep-tech remote monitoring products and industry veterans who have built medical technology unicorns. We aim to become the global gold standard in nocturnal monitoring for everything from drug development and post market surveillance to diagnostics and preventative healthcare in chronic conditions.
Key Facts
– 300M people in the US & EU alone suffer conditions where nocturnal symptoms, days in advance, provide early warning signs of worsening (eg asthma, COPD, Heart failure) – 20M new cases of these conditions each year – 7,000 new clinical trials each year where nocturnal symptoms need to be monitored, involving 2.5M patients – Market size for these 7,000 trials is approx. £4bn – Albus Health’s remote monitoring device is entirely burden-free: patients simply need to plug it into the power socket and set it next to their bedside. There is no training or self-reporting required. – The monitoring device is extremely robust: it can continuously monitor a range of night-time symptoms, irrespective of the patient’s sleeping posture, the presence of bedclothes, co-sleepers, etc. – Our remote monitoring product has been clinically validated against the current gold standards in respiratory medicine, achieving over 98% accuracy and delivery of results 1,000 times faster. Work is ongoing to expand this into other disease areas.
Successes in UK/NHS
As part of our development programme, we secured a £1.6M AI in Health Care Award from the UK Department of Health & Social Care. This has allowed us to work with 2 NHS sites (Royal Brompton Hospital and Birmingham Children’s Hospital) to recruit children with severe asthma into a clinical study. This work will allow us to expand the capability of the Albus Home platform to clinical care, predicting the onset of asthma attacks in these patients. In the UK clinical trials market, Albus has seen success with several ongoing paid contracts for supply of our devices and data analytics, including a programme with AstraZeneca.Company details
Solutions
Delivering advanced patient care
Driving insights and analysis
Specialism
Drug discovery and Clinical trials
Long-term condition monitoring
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.albushealth.comMarkets already exporting to
None
Desired Markets
Clinical trials market is global, but focus on USA, EU/EEA, Japan
Desired customer types
Pharmaceutical companies, clinical researchers, government healthcare systems, private healthcare groups, individual hospitals and clinical departments.